14 January 2013

Oxyrane Opens New Operation in Massachusetts, USA

- Oxyrane head office is in Manchester, England

Manchester, England – 14 January 2013 (BUSINESS WIRE) - Oxyrane, a privately-owned biotechnology company with a head office in Manchester, (England) and research operations in Gent, (Belgium), announced today that it has opened a new operation in Burlington, Massachusetts (USA). The new operation is an important step in the company’s evolution as it progresses clinical development of its innovative enzyme replacement therapy-based solution that has the potential to address numerous unmet clinical needs across a range of lysosomal storage disorders (LSDs).

“Establishing a dedicated operation in the United States strengthens our presence in the largest healthcare market in the world and Massachusetts is the capital of orphan disease drug development,” said Philip Astley-Sparke Non-Executive Chairman of the Board of Oxyrane. Philip, who was previously President and Chief Executive Officer of BioVex Group, Inc, now part of Amgen, provides a wealth of valuable experience in the development of biologics, having spent 11 years directing the successful development of BioVex from an early stage to an established company. In his role as Non-Executive Chairman, he is focussing predominantly on overseeing the shaping of Oxyrane’s commercial plans and increasing its market profile. 

As part of the process of building a US operation, Oxyrane has made a number of senior appointments. The first step was to appoint Dr Charles “Charlie” Richard as Chief Medical Officer. Charlie is an expert in LSDs with over 10 years’ drug development experience in the rare and orphan disease space. He joins from Shire Human Genetic Therapies where, since 2006, he was Principal Medical Director and Head of Translational Medicine in Clinical R&D. 

Dr Richard has made two further senior appointments, based at the Burlington office. 

James “Jim” Weston, Vice President of Regulatory Affairs – Jim has over 30 years’ experience in the development of biological and pharmaceutical products and has directed strategy for development programs in the US, Canada, Europe, Australia and Japan resulting in the approval of 11 drugs/biologics worldwide. James joins Oxyrane from his previous role as US Head of Regulatory Affairs for rare and orphan diseases at Shire Human Genetic Therapies. 

Susan Flint, Executive Director and Head Clinical Operations – Susan is an accomplished senior executive with over thirty years’ experience in multinational drug development including: executive management, regulatory affairs, clinical operations and has led several international multi-million dollar clinical trials in a variety of therapeutic areas. Susan joins Oxyrane from her previous role as Program Director at Navidea Biopharmaceuticals. 

Commenting on the on the establishment of a US operation, Michael Campbell, Chief Executive Officer of Oxyrane, said, “We now have in place a top team of commercial, clinical and regulatory experts with a proven track record of success in the orphan space. I look forward to working with them as we progress towards developing our clinical programme and beyond.” 

Source: Oxyrane